Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 9/20 | 0.62 |
| ▸ | GPR6 | P46095 | 4/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031369 | 0.92 | CHEK1 (0.55) | CHEK1GPR6IDO1CDK5CDK5R1 | |
| SCHEMBL2034536 | 0.90 | CHEK1 (0.64) | CHEK1CDK5CDK5R1RPS6KA3SRPK1 | |
| SCHEMBL5165492 | 0.88 | CHEK1 (0.59) | CHEK1CDK5CDK5R1RPS6KA3SRPK1 | |
| SCHEMBL12643246 | 0.83 | CHEK1 (0.53) | CHEK1CDK5CDK5R1RPS6KA3SRPK1 | |
| SCHEMBL2034018 | 0.81 | CHEK1 (0.54) | CHEK1CDK5CDK5R1RPS6KA3SRPK1 | |
| SCHEMBL2031893 | 0.81 | CHEK1 (0.49) | CHEK1CDK5CDK5R1 | |
| SCHEMBL14355064 | 0.79 | CHEK1 (0.76) | CHEK1RPS6KA3SRPK1HSP90AA1HSP90AB1 | |
| SCHEMBL2036348 | 0.78 | CHEK1 (0.51) | CHEK1IDO1CDK5CDK5R1RPS6KA3 | |
| SCHEMBL4298507 | 0.77 | CHEK1 (1.00) | CHEK1RPS6KA3SRPK1 | |
| SCHEMBL2034851 | 0.77 | CHEK1 (0.51) | CHEK1CDK5CDK5R1RPS6KA3SRPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379510-B1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHEMOSENSITIZERS | ICOS CORP (US) | 2011-06-01 | — | — | EP | claimed |
| JP-4222833-B2 | — | — | 2009-02-12 | — | — | JP | claimed |
| US-7067506-B2 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (US) | 2006-06-27 | — | — | US | claimed |
| JP-2004523568-A | — | — | 2004-08-05 | — | — | JP | claimed |
| EP-1379510-A1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS | ICOS CORPORATION (US) | 2004-01-14 | — | — | EP | claimed |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2003-04-10 | — | — | US | claimed |
| WO-2002070494-A1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS | ICOS CORPORATION (US) | 2002-09-12 | — | — | WO | claimed |
| EP-1379510-B1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHEMOSENSITIZERS | ICOS CORP (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-1379510-B1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHEMOSENSITIZERS | ICOS CORP (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7067506-B2 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2005-11-03 | — | — | US | disclosed |
| EP-1379510-A1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS | ICOS CORPORATION (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2003-04-10 | — | — | US | disclosed |
| WO-2002070494-A1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS | ICOS CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, PCNA, CHEK2 | CHEK1 1/4885GPR6 3892/4885IDO1 3010/4885 |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | CHEK1, PCNA, CHEK2 | CHEK1 1/4885GPR6 3892/4885IDO1 3010/4885 |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | CHEK1, PCNA, CHEK2 | CHEK1 1/4885GPR6 3892/4885IDO1 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.